Senate Legislation Targets Federal 340B Drug Program with Stricter Transparency and Oversight Standards

Last updated: August 19, 2026

NewsWK — Federal lawmakers are advancing efforts to reform one of the nation’s largest and fastest-growing healthcare initiatives, introducing comprehensive legislation aimed at overhauling the federal 340B Drug Pricing Program. Known formally as the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act, or S. 5244, the bipartisan measure seeks to establish clear statutory guardrails, bolster reporting requirements, and ensure that discounted prescription drugs directly benefit low-income patients and vulnerable communities across the United States.

The introduction of the legislation marks a significant step in the long-running congressional debate over how the 340B program operates. Originally created to help safety-net healthcare providers stretch scarce federal resources, the program has grown exponentially over the past three decades, prompting increased scrutiny from fiscal conservatives, healthcare analysts, and federal watchdogs who argue that a lack of transparency has allowed large hospital networks to generate substantial revenues without demonstrating measurable benefits for needy patients.

Why it matters here

For patients, taxpayers, and healthcare providers across the United States, the federal 340B program plays a pivotal role in the economics of local healthcare delivery. When functioning as intended, the program requires pharmaceutical manufacturers participating in Medicaid and Medicare Part B to provide substantial discounts—often between 20 and 50 percent—on outpatient drugs sold to qualifying healthcare organizations. These organizations include federally qualified health centers, critical access hospitals in rural areas, and urban safety-net facilities.

However, the rapid expansion of the program has raised practical questions for local communities:

• Patient Affordability: Proponents of reform emphasize that current federal statute does not explicitly require covered entities to pass drug discounts directly along to uninsured or underinsured patients at the pharmacy counter.
• Rural Healthcare Stability: Small, rural hospitals rely heavily on 340B savings to maintain essential, unprofitable service lines such as maternity care, emergency services, and oncology clinics.
• Taxpayer Accountability: A lack of standardized reporting makes it difficult for federal regulators and local taxpayers to track how tens of billions of dollars in annual drug discounts are utilized by non-profit hospital systems.

Core Provisions of the SUSTAIN 340B Proposal

The legislative text of S. 5244 focuses on several disputed areas within the program that have triggered extensive litigation between healthcare systems, pharmaceutical companies, and federal agencies in recent years. Key elements of the reform effort address contract pharmacy arrangements, patient eligibility definitions, and mandatory reporting.

Over the last decade, participating hospitals have increasingly partnered with third-party, commercial retail and specialty pharmacies to dispense discounted medications. While hospital administrators view contract pharmacies as vital access points for patients living far from central facilities, critics argue the practice has transformed a targeted safety-net initiative into a profit driver for corporate pharmacy chains and third-party administrators. The legislation seeks to create clear rules governing contract pharmacy networks, establishing federal oversight while safeguarding legitimate patient access.

In addition, the measure aims to resolve long-standing ambiguity surrounding the definition of an eligible 340B patient. By clarifying which clinical encounters qualify for discounted pricing, the bill seeks to prevent duplicate discounts, where a single drug purchase receives both a 340B markdown and a statutory Medicaid rebate, an outcome explicitly prohibited under federal law.

Background and the Expansion of the Safety-Net Program

Congress enacted the 340B program in 1992 under Section 340B of the Public Health Service Act. At its inception, the program encompassed a relatively small group of specialized clinics and public hospitals treating underserved populations. Over subsequent decades, legislative changes and regulatory adjustments significantly broadened eligibility criteria, allowing a wider array of private, non-profit hospital systems to qualify.

According to federal oversight reviews and industry analyses, total purchases under the 340B program have surged from approximately $6 billion a decade ago to more than $50 billion annually, making it the second-largest federal drug program behind Medicare Part D. This rapid expansion has intensified calls on Capitol Hill for enhanced reporting mechanisms, requiring participating entities to disclose total 340B revenues, charity care expenditures, and detailed documentation on how program savings are reinvested locally.

The Policy Debate and Next Steps

The debate surrounding 340B reform reflects differing philosophies on federal healthcare governance. Free-market advocates and fiscal conservatives have consistently urged Congress to impose strict auditing requirements and ensure the program adheres strictly to its original statutory purpose: serving truly indigent and rural populations without distorting broader pharmaceutical pricing markets.

Conversely, hospital associations and provider groups maintain that flexibility in deploying 340B savings is indispensable. They argue that rigid spending restrictions could jeopardize the financial viability of safety-net facilities operating on negative or paper-thin margins, especially in medically underserved rural counties.

As S. 5244 moves through the legislative process, lawmakers will weigh competing proposals from healthcare providers, patient advocacy organizations, and manufacturers. The outcome of the debate will have lasting implications for pharmaceutical costs, hospital finances, and the integrity of federal healthcare programs nationwide.